Who Owns Vir Biotechnology Stock?
NASDAQ: VIRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 80.89%
- Held by insiders
- 6.63%
- Institutional holders
- 365
- Institutions 80.9%
- Insiders 6.6%
- Public and other 12.5%
Who owns Vir Biotechnology stock?
Institutional investors own about 80.9% of Vir Biotechnology's shares, spread across 365 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 6.63% of VIR.
The largest institutional holders are Blackrock Inc. (13.11%), Arch Venture Management, Llc (7.41%) and Vanguard Portfolio Management LLC (7.02%). Together, the top 10 institutions control 54.3% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their VIR positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of VIR
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 22.45M | 13.11% | +8.6% |
| Arch Venture Management, Llc | 12.69M | 7.41% | -1.7% |
| Vanguard Portfolio Management LLC | 12.02M | 7.02% | +4.6% |
| SB Investment Advisers (UK) LTD | 10.95M | 6.39% | 0.0% |
| GSK plc | 8.55M | 4.99% | 0.0% |
| State Street Corporation | 7.82M | 4.57% | -21.5% |
| Vanguard Capital Management LLC | 6.45M | 3.77% | +0.9% |
| Point72 Asset Management, L.P. | 5.67M | 3.31% | +190.3% |
| Dimensional Fund Advisors LP | 3.32M | 1.94% | +6.3% |
| Geode Capital Management, LLC | 3.02M | 1.76% | -9.8% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of VIR
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 4.85M | 2.83% |
| iShares Trust-iShares Russell 2000 ETF | 3.53M | 2.06% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 3.48M | 2.03% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.55M | 1.49% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 2.00M | 1.17% |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Equity Fund | 1.76M | 1.03% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.40M | 0.82% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.35M | 0.79% |
| iShares Trust-iShares Russell 2000 Value ETF | 1.28M | 0.75% |
| SPDR SERIES TRUST-State Street SPDR Portfolio S&P 600 Small Cap ETF | 1.16M | 0.68% |
Frequently asked questions
Who is the largest shareholder of Vir Biotechnology?
Blackrock Inc. is the largest institutional shareholder of VIR, owning 13.11% of shares outstanding (22.45M shares) as of its latest 13F filing.
What percentage of Vir Biotechnology is owned by institutions?
Institutions own about 80.9% of VIR shares and 86.6% of the public float.
How much of Vir Biotechnology do insiders own?
Insiders, such as officers and directors, own about 6.63% of VIR shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.